BioGenerator Follow-On Funds

Our best ROI opportunities.

BioGenerator Ventures' base investment model deploys funds from an evergreen fund structure where BioGenerator Ventures invests increasing amounts of capital over time into companies that meet milestones. Companies that perform very well across multiple investments from BioGenerator Ventures are then selected for investment from follow-on ROI funds managed by the BioGenerator Ventures team. In selecting follow-on fund investments, the BioGenerator Ventures team benefits from years of working with management teams and technology, choosing only the very best companies for follow-on investment from ROI funds managed by BioGenerator Ventures. A pilot ROI fund, BioGenerator Fund I, was closed in 2017. The final investment from Fund I was made into CoverCress in 2021; the company was acquired by Bayer in 2022.

BioGenerator Ventures portfolio companies selected for follow-on investment from the BioGenerator Fund I pilot:

CoverCress (2018, 2021) (Acquired by Bayer AG in 2022)
Benson Hill (2018) (SPAC merger in 2021; NYSE: BHIL)
Canopy Biosciences (2019) (Acquired by NASDAQ: BRKR in 2020)
Galera Therapeutics (2018) (IPO; NASDAQ: GRTX in 2019)
MediBeacon (2018)
Arch Oncology (2018)
Cardialen (2018)
SentiAR (2018)

Calendar year indicates year of BioGenerator Fund I investment.

Case Studies - Ventures, Case Studies - Labs

MediBeacon

Case Studies - Ventures, Case Studies - Labs

SentiAR

Oct 29, 2020 Press Releases

BioGenerator Company Benson Hill Raises $150M Series D Round

Nov 7, 2019 Press Releases

BioGenerator Company Galera Goes Public with $60M IPO

Sep 11, 2020 Press Releases

BioGenerator Company Canopy Biosciences Acquired by Bruker

Matthew B. Crisp

Co-Founder and CEO, Benson Hill (NYSE:BHIL)

“BioGenerator played a critical role in leading our initial financing - putting together the due diligence and orchestrating additional investors. Their commitment to supporting Benson Hill in multiple ways beyond their share of invested capital is part of the reason we are excited to call St. Louis home.”

Steve Hanley

Co-Founder and CEO, MediBeacon

“The network BioGenerator has is really invaluable and their active support from pre-company licensing through our Series A round was critical in getting the company to where it is today.”

Jennifer Avari Silva

Co-Founder and CMO, SentiAR

“BioGenerator has been instrumental in launching our company—from learning how to be successful academic founders to the details of starting and financing SentiAR, our spin out from Washington University. They have made crucial introductions to industry leaders at appropriate times and invested in our company. We could not have embarked down this path without all the support from the BioGenerator team!”

Crystal Winkeler

VC Fellow at BioGenerator; Co-Founder & COO, Canopy (NASDAQ:BRKR)

“BioGenerator has played a critical role in the development of our company from day one. They conceived of the business model, were instrumental in bringing together the founding team, and led the initial funding of the company. Access to the BioGenerator Labs has also been vital to our early success. We simply wouldn’t exist without the BioGenerator team.”

Bob Karr

Co-Founder and Former CEO, Arch Oncology

“BioGenerator served as the lead investor through multiple rounds of early financing. They played a key role on the board as the company pivoted from its original indications to applications in oncology.”

Al Beardsley

Co-Founder & COO of Galera Therapeutics (NASDAQ: GRTX)

“BioGenerator was a key early supporter of Galera and our first institutional investor. Galera capitalizes on St. Louis’ historical strengths in the discovery of truly innovative small molecule medicines. ”